Liminatus Pharma, Inc. Class A Common Stock reports a Return on Equity (ROE) of 8,383.35%.

What is LIMN's dividend yield?

Liminatus Pharma, Inc. Class A Common Stock offers a dividend yield of 0.00%.

What is LIMN's Quality Score?

Our AI rates LIMN's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy LIMN?

Our AI Timing Score for LIMN is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does LIMN belong to?

Liminatus Pharma, Inc. Class A Common Stock is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Liminatus Pharma, Inc. Class A (LIMN) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-06 | FS: 2026-03-31)

LIMN AI Analysis Summary

Our AI summary for LIMN: Liminatus Pharma, Inc. Class A Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 8,383.35%, a dividend yield of 0.00%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

LIMN

Liminatus Pharma, Inc. Class A Common Stock

US:NASDAQ STOCK Healthcare >> Biotechnology News 92

USD 0.10

-0.01 (-5.81%) Day Change

Watchlist Portfolio Compare Chart

-10.88

D/E

8,383.4%

ROE

-398.4%

ROA

0.00%

Div Yield

LIMINATUS PHARMA, INC. CLASS A COMMON STOCK
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.10 Price -0.01 (-5.81%) Day Change	NEWS SCORE: 92

LIMN, the overall quality is ok ( Quality = 62) and the timing to buy is ...(Sign In to See)...

Loading chart...

62 QUALITY

Signal: NEUTRAL

Signal Description: Company financial health is OK

Reason: ROA is relatively low.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

51%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	92
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.10
PBV / Sector	-53.18 / 5.21
Earning Per Share	-0.16

PE / Sector	N/A / 21.00
PEG or PE/Growth / Sector	N/A / 1.11
Average 1M Daily Value	5.41 M GREAT
Average 1W Daily Value	0.79 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 95.56
NPM Average (%) / Sector	N/A / -1,676.77
NPM Change Average (%) / Sector	N/A / 4,917.73
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-398.39 / 25.44
ROA Average (%) / Sector	-507.51 / -350.66
ROA Change Average (%) / Sector	519.94 / 5,110.09 GREAT
ROE (%) / Sector	8,383.35 / 3.07 GREAT
ROE Average (%) / Sector	1,658.18 / 4.81
ROE Change Average (%) / Sector	2,096.07 / 2,068.02 GOOD
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.02
Dividend Average (%) / Sector	N/A / 17.10
Dividend Change Average (%) / Sector	N/A / 0.98

Registration Details

Analyze Date	2026-08-07 08:11:57
Symbol	LIMN
Name	LIMINATUS PHARMA, INC. CLASS A COMMON STOCK
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	67.16 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	7.05 / 9,672.56

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 12611 Hiddencreek Way, Cerritos, CA, United States, 90703

Phone: 213 273 5453

Website: https://liminatuspharma.com

Sector: Healthcare >> Biotechnology

Description: Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.